Contineum initiates patient dosing in Phase 1B PET trial

Contineum (CTNM) Therapeutics “announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography, PET, trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor. The Phase 1b, open label, single-center trial is expected to measure the correlation of pharmacokinetics to receptor occupancy by PET imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis and progressive multiple sclerosis patients. Contineum anticipates topline data from the PIPE-791 Phase 1b PET trial in the second quarter of 2025. “